Evidence map›Paper›PMID 32571386›Full record

ArticleItalian journal of pediatrics2020

Furosemide use in Italian neonatal intensive care units: a national survey.

Valeria Anna Manfredini, Chiara Cerini, Antonio Clavenna, Andrea Dotta, Maria Letizia Caccamo, Alex Staffler, Luca Massenzi, Rossano Massimo Rezzonico, on the behalf of study Group of Neonatal Pharmacoterapy of the Italian Society of Neonatology

Open access · goldAbstract read
In one paragraph

Article in Italian journal of pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Use of diuretics in the neonatal period.Pediatric nephrology (Berlin, Germany) · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Valeria Anna ManfrediniNeonatal Intensive Care Unit, ASST Rhodense, Via C. Forlanini 95, 20024, Milan, Italy. valeria.manfredini@yahoo.it.ORCID http://orcid.org/0000-0002-7200-9827
Chiara CeriniChildren's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA, 90027, USA.
Antonio ClavennaDepartment of Public Health, Laboratory for Mother and Child Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Andrea DottaDepartment of Medical and Surgical Neonatology, Neonatal Intensive Care Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Maria Letizia CaccamoIndipedent researcher, Former director of Neonatal Intensive Care Unit, Sant'Anna Hospital, Como, Italy.
Alex StafflerDivision of Neonatology, Central teaching Hospital of Bolzano, Bozen, Italy.
Luca MassenziNeonatology and Neonatal Intensive Care Unit, "San Giovanni Calibita" Fatebenefratelli Hospital, Rome, Italy.
Rossano Massimo RezzonicoIndipendent researcher, Former director of Neonatal Intensive Care Unit, ASST Rhodense, Via C. Forlanini 95, 20024, Milan, Italy.
on the behalf of study Group of Neonatal Pharmacoterapy of the Italian Society of Neonatology
Aziende Socio Sanitaria Territoriale RhodenseBambino Gesù Children's Hospital · ITChildren's Hospital of Los Angeles · USFatebenefratelli Hospital · ITIstituto Ortopedico Gaetano Pini · ITMario Negri Institute for Pharmacological Research · ITOspedale di Bolzano · ITOspedale Sant'Anna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFurosemide is approved in full term neonates to treat edema associated with congestive heart failure, cirrhosis and renal diseases. It is often administered off-label in premature neonates, to treat respiratory conditions and at doses greater-than-recommended. We conducted a national survey on behalf of the Neonatal Pharmacotherapy Study Group of the Italian Society of Neonatology (SIN), to investigate its use in Italian neonatal intensive care units (NICUs), in conformity with current guidelines.

methodsBetween December 2016 and June 2017, a 14-item multiple-choice online questionnaire was sent to all NICU directors from the SIN directory. Gestational age, route of administration, posology, indications, referenced guidelines, adverse effects monitoring and the presence of Paediatric Cardiology or Cardiosurgery service on site were assessed. A chi-square test was performed 1) to evaluate differences in the distribution of responses between NICUs administering furosemide at doses higher-than-recommended; 2) to compare the proportion of NICUs administering furosemide at high doses in institutions with versus without a Paediatric Cardiology or Cardiosurgery service.

resultsThe response rate was 50% (57/114). The intravenous and oral routes were chosen primarily; the intravenous administration in single doses predominated over continuous infusion. Its main therapeutic indications were congestive heart failure/overload (94.7%) and oligo-anuria (87.7%) however furosemide was also frequently used for broncopulmonary dysplasia (50.9%) and respiratory distress syndrome and/or transient tachypnea of the newborn (24.6%). In 28/57 NICUs furosemide was administered at doses higher-than-recommended. In most NICUs the same posology was used in term and preterm neonates. Compared to the total sample, a larger proportion of NICUs administering doses greater-than-recommended referenced current literature for reasons to do so (19.3 and 32.1% respectively). The presence of a Paediatric Cardiology or Cardiosurgery service on site did not correlate with the chosen posology. The majority of NICUs performed acoustic test and renal ultrasound for furosemide exposure greater than 2 weeks.

conclusionsIn Italian NICUs, furosemide is commonly prescribed to term and preterm newborns for label and unlabeled indications. Doses greater-than-recommended are frequently administered. Such use is not necessarily inappropriate. More research is required to assess the efficacy and safety of unlabeled use.

Indexed as

Critical CarePractice Patterns, Physicians'FurosemideGuideline AdherenceHumansInfant, NewbornIntensive Care Units, NeonatalItalyOff-Label UseSodium Potassium Chloride Symporter InhibitorsSurveys and QuestionnairesFurosemideSodium Potassium Chloride Symporter InhibitorsFurosemideNewbornOff-labelPosology

Identifiers

PMID32571386
PMCPMC7310123
OpenAlexW3036277806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.